Clinical Trials Logo

Citation(s)

  •   Epperson CN, Hantsoo LV
    Making Strides to Simplify Diagnosis of Premenstrual Dysphoric Disorder. Am J Psychiatry. 2017 Jan 1;174(1):6-7. doi: 10.1176/appi.ajp.2016.16101144.
  •   Epperson CN, Pittman B, Czarkowski KA, Stiklus S, Krystal JH, Grillon C
    Luteal-phase accentuation of acoustic startle response in women with premenstrual dysphoric disorder. Neuropsychopharmacology. 2007 Oct;32(10):2190-8. Epub 2007 Feb 21.
  •   Hantsoo L, Epperson CN
    Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiol Stress. 2020 Feb 4;12:100213. doi: 10.1016/j.ynstr.2020.100213. eCollection 2020 May.
  •   Hantsoo L, Epperson CN
    Premenstrual Dysphoric Disorder: Epidemiology and Treatment. Curr Psychiatry Rep. 2015 Nov;17(11):87. doi: 10.1007/s11920-015-0628-3. Review.
  •   Hantsoo L, Golden CEM, Kornfield S, Grillon C, Epperson CN
    Startling Differences: Using the Acoustic Startle Response to Study Sex Differences and Neurosteroids in Affective Disorders. Curr Psychiatry Rep. 2018 May 18;20(6):40. doi: 10.1007/s11920-018-0906-y. Review.
  •   Hantsoo L, Grillon C, Sammel M, Johnson R, Marks J, Epperson CN
    Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder. Psychopharmacology (Berl). 2021 Oct;238(10):2985-2997. doi: 10.1007/s00213-021-05916-6. Epub 2021 Jul 22.

Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder

Details for clinical trial NCT02777372